Introduction
Dyslipidemia is a major risk factor for cardiovascular disease (CVD). The deposition of plasma lipids in the arterial intima induces a local inflammatory response and extensive vascular remodelling resulting in the formation of atherosclerotic plaques (1). Plaque rupture or erosion causes myocardial infarction or stroke. The prevalence of dyslipidemia, characterized by elevated plasma triglyceride (TG) and low HDLcholesterol (HDL-C), in combination with obesity, elevated blood glucose levels and/or hypertension termed the metabolic syndrome (MS), increases worldwide, mainly due to a sedentary lifestyle (increased caloric intake, decreased exercise). In addition to a higher incidence of CVD, individuals with the MS are at a higher risk to develop type 2 diabetes (T2D), which further increases the risk for CVD, the most common cause of death from T2D (http://www.who.int/mediacentre/factsheets/fs312/en/index.html).
Obesity and T2D are associated with non-alcoholic fatty liver disease (NAFLD), a pathophysiological accumulation of lipids in the liver (steatosis), which, associated with inflammation, evolves into non-alcoholic steatohepatitis (NASH). NASH may cause cirrhosis and cancer and in the case of complete liver failure, transplantation is the only option (2). Therefore, an appropriate management of the MS is essential to prevent these associated metabolic disorders. The most efficaceous treatment consists of lifestyle changes, which is, however, often difficult to implement due to a lack of patient compliance. A combination of drugs may thus be needed, targeting each single disorder to manage the patient's global risk. Thus, the development of drugs with a combined effect on different risk factors may yield a more effective and improved treatment of the MS.
Before the arrival of statins, hypercholesterolemia was mainly treated with bile acid sequestrants (BAS), which bind bile acids (BA) in the intestine and remove them from 
Bile acid receptors
The best studied BA receptors are the nuclear receptor FXR and the membrane receptor TGR5 (13). Noteworthy, BA can also activate other nuclear receptors such as the human steroid and xenobiotic receptor (SXR) and its rodent homolog pregnane X receptor (PXR), vitamin D receptor (VDR) and constitutive androstane receptor (CAR) (14, 15).
These receptors are also implicated in lipid and glucose metabolism, but their activation seems to occur at non-physiological BA concentrations. Thus, we will focus on FXR-and TGR5 is a member of the rhodopsin-like superfamily of G-protein coupled receptors with most important expression levels in gallbladder, ileum and colon (24). Primary and secondary BA activate TGR5 (13, 24, 25). TGR5 activation leads to receptor internalization and liberation of the Gαs subunit, which activates adenylate cyclase subsequently inducing cAMP production and protein kinase A activation (PKA). PKA phosphorylates the cAMP-response element-binding protein (CREB) and induces the transcription of its target genes (13, 26).
Functions of bile acid receptors

FXR and lipid metabolism
The FXR-mediated regulation of BA synthesis, which represents a major pathway of cholesterol catabolism, suggests an implication of FXR in the control of lipid metabolism.
Indeed, mice deficient for FXR are dyslipidemic with elevated plasma TG, HDL-C as well as non-HDL-C levels (27-29).
The increase of non-HDL-C in FXR-deficient mice occurs both in the VLDL and LDL lipoprotein fraction illustrated by an elevation of plasma apoB concentrations (27, 28).
Hepatic LDL receptor (LDLR) expression is not different, but the production of TG-rich, apoB-containing lipoproteins as well as intestinal cholesterol absorption are increased, probably causing the elevated non-HDL-C levels upon FXR-deficiency (27). In the same line, FXR activation in mice with a synthetic FXR agonist reduces intestinal cholesterol absorption by 50% (30). The authors propose a reduction in BA pool size and hydrophobicity index (due to an increased tauro-β-MCA/TCA ratio) upon FXR activation by guest, on September 21, 2017 www.jlr.org Downloaded from (31) as underlying mechanism, since a reduced BA pool hydrophobicity has been associated with a decrease in cholesterol absorption (32).
The activation of FXR by CDCA in a human hepatocyte cell line results in an increase of LDLR expression and activity (33, 34). In addition, FXR activation potentiates LDLR activity by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a LDLR inhibitor (35). Both effects suggest that FXR activation could lower plasma LDLcholesterol (LDL-C) in vivo. However, CDCA treatment in humans has no effect or even increases LDL-C (36, 37), possibly due to the FXR-dependent inhibition of CYP7A1 resulting in a decreased demand in cholesterol for BA synthesis and a decreased LDL uptake. In the same line, BAS, which de-activate FXR by limiting the availability of endogenous ligands, lower LDL-C (3, 38). Due to the increase in BA synthesis, endoplasmatic reticulum cholesterol is depleted, thus activating the sterol regulatory element binding protein (SREBP)2 which in turn upregulates LDLR expression (38, 39).
Recently, it has been demonstrated that CA represses human LPA gene expression in transgenic mice in a FXR-dependent manner. The corresponding protein, apo(a), covalently binds to apoB forming lipoprotein(a) (Lp(a)), a plasma lipoprotein strongly associated with a high risk for the development of athero-thrombotic diseases (40).
Further, in patients with biliary obstruction and thus elevated plasma BA levels, plasma Lp(a) concentrations are very low, but return to normal levels after sucessful removal of the obstruction (40). Thus, regarding the management of Lp(a) levels and the associated atherosclerosis risk, FXR activation, which may exert positive effects on pro-atherogenic apoB-containing lipoproteins, appears to be indicated.
The elevation of HDL-C observed in FXR-deficient mice is associated with the presence of larger HDL particles and a reduced uptake of HDL-C esters by the liver due to a by guest, on September 21, 2017 www.jlr.org Downloaded from decreased expression of the HDL receptor, scavenger receptor class B member 1 (SR-BI) (27, 30). Accordingly, the administration of an FXR ligand decreases HDL-C levels, which is associated with an increase of hepatic SR-BI expression and of hepatic cholesterol clearance (30). HDL-C modulation by FXR is apoAI-independent, since apoAI expression is not altered in liver or ileum of FXR-deficient mice (27) or upon FXR activation (30).
FXR further induces the expression of the phospholipid transfer protein (PLTP) (41), which contributes to HDL remodeling (42). These data suggest that FXR activation in mice promotes reverse cholesterol transport, however, reflected by a decrease in HDL-C.
In contrast, the human APOA1 gene is repressed by BA treatment in primary human hepatocytes in vitro and in mice overexpressing the human transgene (43). Possible mechanisms include FXR binding to a negative FXRE in the APOA1 promoter (43), the induction of SHP, which inhibits LRH-1-mediated APOA1 induction, (44) or FXRindependent mechanisms (45). Thus, the effects of FXR activation on HDL-C in humans remain uncertain.
As mentioned above, FXR-deficient mice present increased plasma TG levels, implying a role for FXR in TG metabolism. In the absence of FXR, the hepatic synthesis rate of TGrich lipoproteins is elevated even though mRNA levels of apoB are unaltered and mRNA levels of microsomal TG transfer protein (MTP), a protein involved in VLDL assembly and secretion, are decreased (27). FXR activation improves plasma TG clearance in wildtype, but not in FXR-deficient mice, by increasing apoCII and decreasing apoCIII expression, a lipoprotein lipase activator and inhibitor, respectively (46, 47). In addition, FXR activation induces VLDL receptor expression, which is known to contribute to plasma TG clearance (48) . Furthermore, FXR inhibits hepatic lipogenesis by repressing SREBP1c in a SHP-dependent manner (49) . In genetically obese mice, FXR-deficiency strongly increases plasma TG levels (50), as observed in lean animals (27, 28). While the hepatic production of VLDL is unaltered in this model, the decreased expression of apoCII points towards reduced clearance as the underlying cause (50) . Conversely, the administration of natural or synthetic FXR agonists decreases plasma TG in mouse and hamster models of obesity (49, 51) . In both studies, VLDL production decreases upon FXR activation, which has been linked to a reduction of hepatic lipogenesis and TG content (49, 51) .
In normo-and hypertriglyceridemic patients, reduction of the BA pool by BAS treatment results in elevated plasma TG levels due to an increased VLDL production (52) .
Likewise, patients with CYP7A1-deficiency display elevated plasma TG (53) . In vitro, FXR activation in a human hepatocyte cell line decreases MTP expression and the secretion of VLDL (54) . Consequently, the administration of CDCA to patients with hypertriglyceridemia reduces plasma TG (55, 56) .
In line with the inhibitory function of FXR on hepatic lipogenesis (49), FXR-deficiency leads to a mild steatosis in lean mice (28) and to an exacerbation of hepatic TG content in genetic (ob/ob) obesity (50), whereas FXR activation with different agonists improves hepatic steatosis (49, 57) . These findings have raised the intriguing possibility, that FXR may also be implicated in the progression of steatosis to NASH. Indeed, FXRdeficiency in LDLR-deficient mice fed a high-fat diet leads to the development of NASH with infiltration of inflammatory cells and deposition of extracellular collagen (58) . The administration of a synthetic FXR agonist reverses inflammatory infiltration and fibrosis in a FXR-dependent manner in mice fed a methionine-, choline-deficient diet (59) . Overall, both in mice and humans FXR activation improves hypertriglyceridemia and decreases steatosis. Thus, FXR activation might be useful to improve hepatic steatosis and even NASH.
FXR and atherosclerosis
Loss of FXR function in mouse models of atherosclerosis has produced contradictory results depending on the animal model and gender. On the one hand, the absence of FXR in apoE-deficient mice fed an atherogenic diet leads to more severe atherosclerosis with a decreased survival rate (60) . On the other hand, FXR-deficiency in LDLR-deficient mice is atheroprotective (61, 62) . The effect of FXR activation on decreasing atherosclerotic plaque burden seems in part due to an improvement of the lipid profile (63-65). Overall, FXR activation appears to protect against atherosclerotic plaque formation.
FXR and glucose metabolism
The expression of both FXR and CYP7A1 is increased by glucose and decreased by In contrast, a recent third paper shows that FXR activation by the synthetic agonist GW4064 in mice with diet-induced obesity aggravates glucose intolerance by reducing the BA pool size. Consequently, the administration of BA restores the BA pool and reverses the GW4064-induced metabolic effects (89). In line with this concept, FXRdeficiency has been shown to protect from genetic and diet-induced obesity (50, 90) and to improve glucose homeostasis by increasing peripheral glucose clearance and adipose tissue insulin sensitivity (50) . The deletion of hepatic FXR has no protective effect (50) highlighting the importance of extra-hepatic FXR.
Even though partly controversial, these data provide evidence for a regulatory role of FXR in glucose metabolism and insulin sensitivity. FXR might exert differential effects in lean versus obese mice. Tissue-specific models might be necessary to dissect the complex effects of FXR on insulin resistance. From a pharmacological viewpoint, it is by guest, on September 21, 2017 www.jlr.org Downloaded from unclear whether inhibition or activation of FXR would be most efficient to correct altered glucose metabolism.
TGR5 and energy metabolism
Mice deficient for TGR5, the membrane receptor for BA, exhibit a decreased BA pool size even though fecal BA excretion is unaltered (91). In addition, they are protected from gallstone formation (92) . TGR5 is expressed in human cholangiocytes (gallbladder epithelial cells) (93) and is involved in regulating bile composition by inducing chloride secretion by cholangiocytes (94) . Treatment with the TGR5 agonist INT-777 stimulates gallbladder filling (95) .
Interestingly, TGR5 also regulates metabolic homeostasis. Whereas TGR5-deficient mice have normal weight and fat mass (92) , when fed a high-fat diet females display increased weight gain resulting from increased fat accumulation (91). Conversely, TGR5 activation by supplementing CA to the diet prevents the high-fat-induced changes in adipose tissue mass and morphology (96) . The role of TGR5 in weight loss has been associated to an increased energy expenditure and not to a decreased caloric intake (96) . TGR5 activation induces deiodinase-2 expression in murine brown adipose tissue 
TGR5 and lipid metabolism
TGR5 also affects hepatic lipid content. Female TGR5-deficient mice present an increase in hepatic fat content especially when fed a high-fat diet (92) . In line, TGR5 activation with INT-777 improves liver function by decreasing steatosis and preventing fibrosis (98) . Additionally, plasma TG and non-esterified fatty acid levels are decreased upon TGR5 activation (98) . Thus, TGR5 activation might be useful for the treatment of NAFLD.
TGR5 and atherosclerosis
A recent study has reported anti-atherosclerotic effects of TGR5 activation (99) . The administration of INT-777 to LDLR-deficient mice attenuates atherosclerotic lesion size only in the presence of TGR5 due to a decrease in plaque macrophage content and intraplaque inflammation. This effect is attributed to TGR5-induced cAMP signaling in macrophages, causing the inhibition of nuclear factor κ light-chain enhancer of activated B cells (NF-κB) activity and the subsequent production of pro-inflammatory cytokines (99) .
TGR5 and glucose homeostasis
In mice fed a high-fat diet, TGR5 activation lowers serum glucose and insulin levels and improves glucose tolerance (97, 98) . TGR5-transgenic (TGR5-tg) mice also display improved diet-induced glucose intolerance without changes in body weight (98) . TGR5 activation induces glucagon-like peptide-1 (GLP-1) production by enteroendocrine cells (98) . Furthermore, enhanced plasma GLP-1 in TGR5-tg mice fed a high-fat diet is associated with a normal pancreatic islet distribution and higher insulin content compared to hypertrophic islets with low insulin content in high-fat diet-fed control mice (96) . In contrast, TGR5-deficient mice have impaired glucose tolerance and INT-777 treatment has no effect on GLP-1 secretion in these mice (98) . In humans, a genetic variation within the TGR5 gene is, however, not associated with the development of prediabetic phenotypes (102) .
Modulators of bile acid receptor activity and their clinical application
As outlined above, FXR and TGR5 contribute to the regulation of a panel of pathways linking BA and metabolic homeostasis. As a result, both receptors are potential targets for the treatment of cholestasis, hyperlipidemia, NAFLD/NASH, CVD and T2D.
Consequently, an extensive effort has been put into the identification and development of modulators of FXR and TGR5 activity. In the following, we will discuss the available compounds and the status of their (pre)clinical evaluation (Table 1 and Figure 1 ).
FXR agonists
Endogenous primary (CDCA, CA) and secondary (LCA, DCA) BA activate FXR with different efficacy (CDCA > LCA = DCA > CA) with the conjugated forms being less potent (103, 104 Before BA were known to activate FXR, CDCA was tested for the treatment of gallstones in order to enrich the bile and dissolve the stone. Four studies in small patient cohorts (n=8-15) find a reduction in plasma TG (55, 56, 105, 106) , but no change in total plasma cholesterol (55, 56, 106) , and one reports decreased HDL-C levels (105) . The only study conducted in a large number of patients (n=916) observes an increase of LDL-C upon CDCA administration (36). Thus, even though CDCA treatment lowers elevated plasma TG levels, the impact on cholesterol metabolism is not conclusive and might rather be unfavourable. In addition, elevated liver enzymes and diarrhea might occur as side effects (36, 56) discourageing the use of CDCA in the clinic. Nevertheless, a study has recently been launched in patients with MS and dyslipidemia (scheduled n=48) to test the effect of CDCA on plasma TG levels, defined as primary endpoint, hepatic fat content to be determined by nuclear magnetic resonance and hepatic glucose metabolism to be measured by hyperinsulinemic euglycemic clamp analysis (http://clinicaltrials.gov; NCT00465751).
A procyanidin extract from grape seeds reduces postprandial plasma TG levels in wildtype, but not in FXR-or SHP-deficient mice, decreases the expression of lipogenic genes such as SREBP1c and enhances the transcriptional activity of FXR, though only in the presence of CDCA (107, 108) . However, it is unknown which component of the extract exerts these effects. Further, cafestol, a diterpene present in unfiltered coffee, activates FXR as well as PXR. Cafestol treatment of APOE3Leiden mice increases total plasma cholesterol and consistently represses CYP7A1 and CYP8B1 expression in wildtype, but not in FXR-deficient mice (109) . The most clinically-advanced FXR agonist is the semi-synthetic compound INT-747 (6-Ethyl-CDCA or obeticholic acid), which was designed based on the structure of CDCA and is 10x more potent (110) . Results from in vitro and in vivo studies indicate that INT-747 exerts a hepatoprotective effect in acute LCA-induced necrosis (110) , fibrosis (111) and cholestasis (112) and further protects from insulin resistance and hepatic steatosis in genetically obese rats (113) . However, GW4064 presents some major pharmacodynamic limitations: a certain toxicity due to the stilbene moiety, a poor bioavailability and the difficulty to target extra-hepatic tissues due to a fast metabolization by the liver. Thus, quite an effort has been made to develop GW4064 analogs with comparable potency and improved biological compatability (116, 117) , however, none of which has yet passed beyond preclinical testing. In addition, a number of GW4064 analogs are handled by BAtransporters and conjugated like BA, leading to very low plasma levels and hepatic accumulation (118) . Altogether, accumulating proof from animal and human studies shows that FXR activation reduces hypertriglyceridemia, improves insulin resistance and NAFLD, but has unfavorable effects on cholesterol concentrations. Further studies are necessary to assess the full potential of FXR agonists in the clinic.
FXR antagonist(s)
The only FXR antagonist so far described is guggulsterone, found in the oleoresin of the guggul tree (= guggulipid published, but only one has been conducted in a double-blind, randomized and placebocontrolled manner using a guggulipid with standardized guggulsterone content.
Hypercholesterolemic adults (n=61) were treated with 50mg guggulipid twice daily for 24 weeks in addition to a fruit-and vegetable-enriched diet. The treatment decreases plasma TG as well as total and LDL-C levels, whereas HDL-C does not change (129) . In a second double-blind, randomized, placebo-controlled study performed in a Western population of hyperlipidemic adults consuming a normal Western diet (n=103), a guggul extract containing 2.5% guggulsterone was administered 3 times daily (1g and 2g per dose) for 8 weeks. No changes are observed in plasma TG, VLDL, total cholesterol or HDL-C, but LDL-C levels increase 4-5% compared to placebo controls (130) . The reasons for these contradicting results are unclear.
Selective bile acid receptor modulators (SBARMs)
As AGN34 is a selective FXR modulator, which in the intestinal cell line Caco-2 inhibits the intestinal BA binding protein (IBABP) without affecting SHP expression, both direct FXR target genes (133) . In HepG2 cells, AGN34 again has no effect on SHP, decreases CYP7A1 expression, leading to the conclusion that AGN34 acts as an antagonist on IBABP expression, but as an agonist on CYP7A1 expression, hence as a gene-selective modulator (133) . However, the mechanism by which AGN34 lowers CYP7A1 expression in a SHP-independent manner in isolated hepatocytes remains unknown.
TGR5 agonists
In comparison to FXR, no TGR5 agonist has entered a clinical trial yet. However, TGR5
modulators are expected to be useful for the treatment of T2D and an emerging function of TGR5 in monocytes and macrophages (134) A natural occuring triterpene from olive tree leaves, oleanolic acid, also activates TGR5.
Addition of oleanolic acid to a high-fat diet tends to reduce weight gain and improves glucose tolerance in mice (97) . Oleanolic acid also attenuates colitis in a murine model, suggesting a role for TGR5 in intestinal barrier function (135) . Another triterpene, betulinic acid, also exhibits TGR5 activating properties. However, derivatives of the compound with an improved potency have no effect on obesity or glucose tolerance in vivo (136) .
As for FXR, a semi-synthetic, steroidal derivative of CDCA has been developed which is a 
Bile acid sequestrants (BAS)
BA homeostasis, and by deduction the activity of BA receptors, can be modulated by BAS, non-absorbable resins that complex BA in the intestinal lumen and direct them (38)).
Part of the LDL-C-lowering and TG-increasing effects of BAS might be mediated by FXR.
Relieve of FXR-mediated inhibition of lipogenesis increases hepatic steatosis at least in rodents (150) . Administration of colestimide for 24 weeks lowers ALT and AST, but not GGT in NASH patients. Unfortunately, the effect on NASH itself has not been evaluated by histological analysis of a follow-up biopsy (151) . Thus, the effect of BAS on hepatic steatosis and NASH remains to be determined.
BAS also lower blood glucose in T2D patients reducing both fasting plasma glucose and HbA1c levels (152) (153) (154) . Inadequately controlled T2D patients on insulin, sulfonylurea or metformin therapy also benefit from BAS administration in terms of glucose control (155) (156) (157) . Surprisingly, the glucose-lowering effect of BAS appears not to be mediated by an improvement of insulin sensitivity as measured by hyperinsulinemic euglycemic clamps (158) , glucose or meal tolerance tests (159) (160) (161) . In contrast, one week administration of colestimide in T2D patients (n=16) lowers plasma glucose and increases postprandial GLP-1 (162) . A second study evaluating glucose kinetics in T2D patients after BAS treatment finds improved glucose clearance and increased GLP-1 and gastric inhibitory peptide (GIP) concentrations (163) . Also, in diabetic rat models BAS decrease plasma glucose and improve glucose tolerance associated with an increase in plasma GLP-1 (164, 165). Beysen et al. further observe no effect of BAS treatment on hepatic glucose production (163) similar as reported in a diabetic mouse model (166) .
Thus, the contribution of FXR to the effects of BAS is unclear. Instead, it has been by guest, on September 21, 2017
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Downloaded from
proposed that BAS-sequestered BA can activate TGR5 expressed in L-cells of the intestinal wall (100) or, that due to impaired micelle formation unabsorbed long-chain fatty acids stimulate GPR40 (158) , both effects promoting GLP-1 secretion.
Conclusion
Today, the link between BA and metabolic homeostasis is well established. Data (141, 142) 
